Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?

Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first‐line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first‐line therapy may provide at least...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 122; no. 7; pp. 1047 - 1049
Main Authors:	Guijarro‐Muñoz, Irene, Roarty, Emily B., Heymach, John V.
Format:	Journal Article
Language:	English
Published:	United States 01-04-2016
Subjects:	Antineoplastic Agents - administration & dosage Bevacizumab - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Female Humans Lung Neoplasms - drug therapy Male
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first‐line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first‐line therapy may provide at least a modest benefit when it is continued with second‐line chemotherapy. See also pages 000–000
Bibliography:	See referenced original article on pages this issue. 1050–9 SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 ObjectType-Article-3
ISSN:	0008-543X 1097-0142
DOI:	10.1002/cncr.29894